Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,865 matching trials from the live ClinicalTrials.gov search.

Filters: Chapel Hill, North Carolina Clear all

Conditions: Premature Birth, Feeding and Eating Disorders of Childhood
Interventions: Decision Support Tool; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Psoriasis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more

Conditions: Autism Spectrum Disorder, Neurodevelopmental Disorders
Interventions: Parents and Infants Engaged; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 11 Months to 16 Months
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Tobacco Use
Interventions: Newly developed warnings with images at 30% size, FDA proposed text-only warnings at 30% size; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 1,029 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Arthritis, Rheumatoid
Interventions: Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 63
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 53 more

Conditions: Chronic Kidney Disease
Interventions: PRT-201, Placebo; Drug
Lead sponsor: Proteon Therapeutics; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Lipodystrophy, HIV Infections
Interventions: Tesamorelin, Placebo for Tesamorelin; Drug
Lead sponsor: Theratechnologies; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Indio, California + 20 more

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 5,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 146
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 123 more

Conditions: Opioid Prescribing
Interventions: Usual Care, Opioid Stewardship Intervention; Other · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Wilmington, North Carolina

Conditions: Burns
Interventions: Routine post burn rehabilitation therapy; Other
Lead sponsor: American Burn Association; Other
Eligibility: 18 Years to 90 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 14
States / cities: Phoenix, Arizona • Orange, California • Sacramento, California + 11 more

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more

Conditions: Invasive Breast Cancer
Interventions: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, lapatinib; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 103
States / cities: Mobile, Alabama • La Jolla, California • Long Beach, California + 88 more

Conditions: Lung Cancer, Small-cell Lung Cancer
Interventions: Trilaciclib, Lurbinectedin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Chapel Hill, North Carolina

Conditions: Prostate Cancer
Interventions: Prostate cancer treatment DESI; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years and older · Male only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Palo Alto, California • Chapel Hill, North Carolina

Conditions: Type 1 Diabetes
Interventions: REAL-Fam Occupational Therapy Family Coaching; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 2 Years to 99 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Leukemia
Interventions: DNA analysis, DNA methylation analysis, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 77
States / cities: Mountain View, California • Lewes, Delaware • Newark, Delaware + 55 more

Conditions: Perioperative Bleeding, Venous Thrombosis, Arterial Thrombosis
Interventions: Tranexamic Acid, Placebo (Saline), Perioperative hypotension-avoidance strategy, Perioperative hypertension-avoidance strategy; Drug · Other
Lead sponsor: Population Health Research Institute; Other
Eligibility: 45 Years and older
Enrollment: 9,535 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 12
States / cities: New Haven, Connecticut • Weston, Florida • New York, New York + 8 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Prednisone, 177Lu-J591; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Interventions: treprostinil SMI (treprostinil inhalation spray), Placebo (placebo inhalation spray); Combination Product
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more

Conditions: Leukemia, Myelocytic, Acute
Interventions: Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine, Busulfan and Cyclophosphamide, Cyclophosphamide and Total Body Irradiation; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 32
States / cities: Phoenix, Arizona • La Jolla, California • Gainesville, Florida + 27 more

Conditions: HIV-1-infection
Interventions: MGD014; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions: Placebo, PF-05221304; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 60
States / cities: Bakersfield, California • Chula Vista, California • La Jolla, California + 43 more

Conditions: Proliferative Glomerulonephritis With Monoclonal IgG Deposits
Interventions: Daratumumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Jacksonville, Florida • Rochester, Minnesota • Chapel Hill, North Carolina + 1 more

Conditions: Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Interventions: CABA-201 following preconditioning with fludarabine and cyclophosphamide; Biological
Lead sponsor: Cabaletta Bio; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 31
States / cities: Orange, California • San Francisco, California • Aurora, Colorado + 22 more

Search by objective public record fields.

Evaluation of an Interdisciplinary Decision Guide for Infant Feeding Assessment

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders

Little Cigar and Cigarillo Warnings Among US Adults Who Use LCCs

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

Reducing Post-Operative Opioid Prescribing in Southeastern North Carolina

The Relationship of Rehabilitation Therapy Time To The Prevention of Burn Scar Contracture

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Study of Trilaciclib and Lurbinectidin

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

REAL-Fam Feasibility Study for Youth Diabetes Management

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

PeriOperative ISchemic Evaluation-3 Trial

Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy